In a report released on September 8, Joseph Schwartz from SVB Securities maintained a Hold rating on Reata Pharmaceuticals (RETA – Research Report). The company’s shares closed last Friday at $26.50.
According to TipRanks, Schwartz is an analyst with an average return of -6.6% and a 43.51% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, BioMarin Pharmaceutical, and ChemoCentryx.
In addition to SVB Securities, Reata Pharmaceuticals also received a Hold from Robert W. Baird’s Brian Skorney in a report issued on September 8. However, on the same day, Jefferies maintained a Buy rating on Reata Pharmaceuticals (NASDAQ: RETA).
See Insiders’ Hot Stocks on TipRanks >>
RETA market cap is currently $967.2M and has a P/E ratio of -3.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
Read More on RETA:
- Adore Beauty Group (ASX:ABY) shares rise
- Cryptocurrencies to Watch for the Week of September 11
- Desjardins Keeps Their Buy Rating on Dollarama (DLMAF)
- Magna Enters Micromobility Market: Investing in Yulu and Creating Battery-Swapping Business
- Rosenblatt Securities Reaffirms Their Buy Rating on Splunk (SPLK)
